week 2 Flashcards
cardiac arrest
unable to geenrate adequate CO to support o2 demands of tissue
four rhythms:
v fib
pulseless ventriculat rachycardia
pulseless electrical activity (PEA)
asystole
survivial depends on acs or bcls
only proven benefit of cardiac arrest
quality chest compressions
cardiac arrest treatments
1, start CPR
- determine rhythm
shockable: VF and pVT
non shockable: asystole, PEA
VF or VT arrest
- provide shock
work on establishing iv access,
if still in shockable environent, give another shock….
then can give epinephrine…
if pt is still in shockable rhythm.. can give another shock, then give antiaryhmics like amiodarone or lidocaine
pea/asystole
non shockable
if asytole or pea admin epinehrine asap and perform cpr for 2 min
if pt still in nonshockable rhhtm, continue cpr
*note: EPNIPHERINE ONLY. vasopressin no longer epinephrine
cardiac arrest med admin routes
iv
io (intraosseous)
endotracheal (et)
NAVEL
naloxone
atropine
vasopressin
epinephrine
lidocaine
vasoactive agents
enhance organ profusion by increasing arterial and aortic diastolic pressures resulting in increases incoronary and cerebral perfusion pressures
ex: epineohrine
epinephrine
indications:
vf and pulseless vt
pea and asystole
dose: 1mg iv/ io q3-5 min
admin as soon as possible in pea/asystole
antiarrhythmics
no high quality evidence to suggest that any antiarryhtmics routinely during crdiac arrest increases survival
amiodarone
lidocaine
amiodarone
indications
dose
considerations
indications: vf and pulseless vt
dose: 300 mg iv bolus. may repeat 150mg iv bolus
considerations: caution in bradycardia and hypotension, possible qt prolongation
lidocaine
indications
dose
considerations
indications: vf an dpulseless vt
dose: 1.1.5 mg/kg IV/IO
considerations:
consider if amiodarone unavailable, risk/ hx of qt prolongation. study not suggests beenfit of lidocaine
magnesium
indications
dose
considerations
indications: vf, pvt associated with torsades des pointes. NOT TO BE USED IN VF,PVT W. NORMAL QT INTERVAL
dose: 2g iv bolus
considerations
reversible causes of arrest Hs
H
hypovolemia- give fluids
hypoxia-give 100% o2 by mask
hydrogen ions(acidosis)-bicarb not recomomended during o2 arrest
hyperkalemia:suspect in dialysis pts, renal insufficicnecy, drug induced (trt w. calcium chloride or gluconate
temporary measures: (bicarb, insulin and dextrose)
long term: diuresis, kayexalate
hypothermia
reversible causes of cardiac arrest
Toxins (opioids, TCA, etc.)
*give naloxone if suspected I
cardiac Tamponade:
Tenstion pneomothorax
thrombosis(PE and MI)
ischemic stroke SS
sudden onset of focal neurological defecit
dysphasia/dysarthria
hemianopia
weakness
ataxia
sensory
neglect
symptoms are unilateral
NIHSS stroke severity
0: no strok esymptons
1-4: minor stroke
5-15: moderate stroke
16-20: mod-sveere stroke
21-42 seevre stroke
treatment options for ischemic stroke
within 4.5 hr of symptom onset
*fibrinolysis +/- thrombectomy
iv fibronylitics
contraindications
iv fibrinolytics ci
<18
ischemic throjke w.i 3 months
intrcranial surgery w.in 3 months
gi malignancy or hib within 21 days
lmwh within 24hrs
unclear onset time >4.5
intracranial hemmorhage
iv fibrinolytics
alteplase,
tenacteplase
moa: tpa activator, dissolves fibrin
dose:
alteplase: 0.9mg/kg
short acting. can give bolus
tenacteplase: 0.25mg/kg
can give iv push, longer t/2
iv fibrinolytics blood pressure control
goal for bolus: <185/110
goal for infusion <180/105
if pt meets exclusion criteria and alteplase not given, permissive htn is allowed
bp not treated unless >220/110 in effort to perfuse brain
ischemic stroke htn treatment
1st line: labetalol
nicardipine
fibrinolytic complications
systomatic ICH:
d/c alteplas einfusion
treat w. cryocepitate 10u
angioedema
-miantaine airway, hold acei-
post fibrinolytic care
neuro and bp monitoing for 24 hrs
dysphagia and aspiration risk
high dose statin all apts
anti platelets
dvt prophylaxis >24hr post alteplase
anticoags if cardioembolic stroke or hx of a fib